Pharsight

1. List of Cequa drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10441630	SUN PHARM	Topical formulations and uses thereof	Aug, 2033 (10 years from now)
US8980839	SUN PHARM	Topical aqueous nanomicellar, ophthalmic solutions and uses thereof	Aug, 2033 (10 years from now)
US9937225	SUN PHARM	Topical formulations and uses thereof	Aug, 2033 (10 years from now)
US10918694	SUN PHARM	Topical cyclosporine-containing formulations and uses thereof	Feb, 2037 (14 years from now)

Market Authorisation Date: 14 August, 2018

Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).

Dosage: SOLUTION;OPHTHALMIC

Strength	Dosage	Availability
0.09%	SOLUTION;OPHTHALMIC	Prescription

2. List of Restasis drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8648048	ALLERGAN	Methods of providing therapeutic effects using cyclosporin components	Aug, 2024 (1 year, 6 months from now)
US8633162	ALLERGAN	Methods of providing therapeutic effects using cyclosporin components	Aug, 2024 (1 year, 6 months from now)
US9248191	ALLERGAN	Methods of providing therapeutic effects using cyclosporin components	Aug, 2024 (1 year, 6 months from now)
US8685930	ALLERGAN	Methods of providing therapeutic effects using cyclosporin components	Aug, 2024 (1 year, 6 months from now)
US8629111	ALLERGAN	Methods of providing therapeutic effects using cyclosporin components	Aug, 2024 (1 year, 6 months from now)
US8642556	ALLERGAN	Methods of providing therapeutic effects using cyclosporin components	Aug, 2024 (1 year, 6 months from now)
US8292129	ALLERGAN	Dispensing device	Feb, 2031 (8 years from now)
US8561859	ALLERGAN	Dispensing device	Apr, 2032 (9 years from now)
US9676525	ALLERGAN	Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids	Feb, 2034 (11 years from now)
US9669974	ALLERGAN	Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids	May, 2034 (11 years from now)

Market Authorisation Date: 23 December, 2002

Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).; Increase tear production to treat patients with keratoconjunctivitis sicca (dry eye).

Dosage: EMULSION;OPHTHALMIC

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.0005	13 Jan, 2014	1		17 May, 2014	Extinguished

Strength	Dosage	Availability
0.05%	EMULSION;OPHTHALMIC	Prescription

3. List of Verkazia drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7973081	SANTEN	Emulsion compositions containing quaternary ammonium compounds	Jan, 2026 (2 years from now)
US9956289	SANTEN	Emulsion compositions containing quaternary ammonium compounds	Jan, 2026 (2 years from now)
US8524779	SANTEN	Emulsion compositions containing quaternary ammonium compounds	Jan, 2026 (2 years from now)
US9220694	SANTEN	Emulsion compositions containing cetalkonium chloride	Jan, 2026 (2 years from now)
US8298568	SANTEN	Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential	Nov, 2027 (4 years from now)
US9132071	SANTEN	Compositions containing quaternary ammonium compounds	Jun, 2029 (6 years from now)